Table 1.

Clinical demographics of the study population (n=64)

Age, median years (range)	40 (15–54)
Sex
Female, n (%)	55 (86)
Male, n (%)	9 (14)
Race
White, n (%)	54 (84)
African-American, n (%)	10 (16)
Ethnicity
Hispanic, n (%)	3 (5)
Body mass index category
Normal, n (%)	4 (6)
Overweight, n (%)	20 (31)
Obese, n (%)	40 (63)
MS disease duration, mean years (±SD)	8.4 (5.5)
Time since last clinical relapse, mean years (±SD)	4.4 (3.7)
Baseline EDSS score, median (range)	2.3 (1.0–6.0)
Number of previous disease-modifying therapies attempted, mean (±SD)	2.4 (1.3)
Current disease-modifying therapy, n (%)
Natalizumab	15 (23)
Fingolimod	9 (14)
Dimethyl fumarate	8 (12.5)
Interferon	8 (12.5)
Glatiramer acetate	8 (12.5)
Ocrelizumab/rituximab	8 (12.5)
Teriflunomide	5 (8)
Alemtuzumab	2 (3)
None	1 (2)
Time on current disease-modifying therapy, median months (range)	24 (6–216)
Subjects with previous diet attempts, n (%)	41 (64)

EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.